Autolus
Manufacturing · United Kingdom · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
191 Wood White City Ln, London, Greater ...Phone Number
+44 2038296230Website
www.autolus.comRevenue
$92.6 MillionStock Symbol
AUTLIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
4
1
1
1
1
1
About Autolus
Autolus Therapeutics plc is a commercial-stage biopharmaceutical company headquartered in London, United Kingdom, founded in 2014. The company is focused on developing, manufacturing, and delivering next-generation programmed T cell therapies for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus engineers precisely targeted, controlled, and highly active T cell therapies designed to better recognize target cells, break down their defense mechanisms, and eliminate them. The company's lead marketed therapy, AUCATZYL (obecabtagene autoleucel, obe-cel), is an FDA-approved CD19-directed CAR T cell therapy indicated for adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia, and has also received regulatory acceptance for review in Europe. Beyond its approved product, Autolus maintains a pipeline of product candidates in development across hematological malignancies, solid tumors, anRead more
Autolus Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Autolus your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Autolus
Funding: Get notified immidiatlly once Autolus has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Autolus is spiking on competitors!
Check if Autolus has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Autolus recently announced quarterly report
Autolus, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Click to see if Autolus had a recent Job posting/layoffs
Product Launch: Get notified when Autolus launches new products
Recommended Actions
Find VP level buyers at Autolus
Find 3 more new buyers
Compare Similar Companies to Autolus
Compare insights from companies similar to Autolus, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Autolus is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Autolus is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Autolus.
Autolus financials insights
Gather financial insights about Autolus, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series B
$54.3M
2021
Share Placement
$100M
Private Equity
$250M
Autolus Tech Stack
A closer look at the technologies used by Autolus
Most Recent Scoops
Person-Based
Events
Open Position
Person-Based
Events
Open Position
Person-Based
Events
Autolus News & Media
Autolus Therapeutics to Participate in Upcoming Investor Conference
Autolus will present at the H.C. Wainwright Cell Therapy Conference on June 30, 2026.Why Autolus Therapeutics (AUTL) Looks Less Speculative as AUCATZYL Revenue Builds
Autolus Therapeutics plc (NASDAQ:AUTL) is one of the small-cap stocks with potential to rise 1000 percent. Unlike many biotech companies that are still waiting for their first approved product, Autolus already has a treatment on the market. Its drug AUCATZYL, also known as obe-cel, is approved for adults with a hard-to-treat form of blood cancer […]Autolus Therapeutics Receives Prix Galien UK Award
Autolus Therapeutics was awarded Prix Galien UK 2026 Best Biotechnology ProductAutolus Therapeutics to Participate in Upcoming Investor Conferences
Autolus will present and host meetings at two upcoming investor conferences.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Autolus
Sign Up For FreeTo access detailed company insights
Autolus Therapeutics plc is a commercial-stage biopharmaceutical company headquartered in London, United Kingdom, founded in 2014. The company is focused on developing, manufacturing, and delivering next-generation programmed T cell therapies for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell p... Read More
